In breast cancer cells, serglycin is upregulated and is correlated with increasing aggressiveness of tumor cells, as it promotes the expression of degrading enzymes, mesenchymal markers and the secretion of interleukin-8 (IL-8) [70]. The gene discussed is CXCL8; the disease is neoplasm.